GOLDEN, Colo. — January 9, 2026 — PharmaJet®, a company focused on improving the performance and outcomes of injectables through needle-free injection technology, announced that its partner Scancell has reported updated Phase 2 clinical data from the SCOPE study in unresectable advanced melanoma. In this study, Scancell’s iSCIB1+ immunotherapy was
View
GOLDEN, Colo. — June 19, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it has entered into an agreement with Immuno Cure, a prominent developer of DNA vaccines. Under the terms of the agreement,
View
GOLDEN, Colo. — April 17, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, will present insights from several DNA Cancer Vaccine partner trials using PharmaJet’s Precision Delivery Systems™ at the World Vaccine Congress 2025 on April 23, 2025
View
GOLDEN, Colo. — December 10, 2024 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free technology, today announced the publication in NPJ Vaccines of the US Army Medical Research Institute of Infectious Diseases (USAMRIID) Phase 1 clinical trial to evaluate the
View
GOLDEN, Colo. — November 5, 2024 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free technology, today announced their upcoming poster presentation on November 8, 2024 at the Society of Immunotherapy of Cancer (SITC) conference. The poster (#741), entitled Modulating Immune
View
GOLDEN, Colo. — November 16, 2023 — PharmaJet®, a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced the start of the first human clinical trial for a Venezuelan Equine Encephalitis (VEE) vaccine delivered with PharmaJet Precision Delivery Systems. The Phase
View
GOLDEN, Colo. — September 28, 2023 — PharmaJet®, a company that engineers precision delivery systems that overcome the challenges of vaccines and pharmaceuticals delivery, today announced that its partner, Scancell, has received positive data from the first stage in its Phase 2 clinical study for treatment of patients with unresectable
View
GOLDEN, Colo. — June 28, 2023 – PharmaJet®, a company engineering precision delivery systems that overcome challenges of nucleic acid vaccine delivery, today announced that its Tropis® System is now the exclusive intradermal delivery system for two authorized novel Covid-19 vaccines:
View
GOLDEN, Colo. — April 18, 2023 —PharmaJet®, a company engineering Precision Delivery Systems™ (PDS) that overcome the challenges of vaccine delivery, today announced that it received a scope expansion and 3-year extension of its multi-year agreement with the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency
View
Load more